Liver Disease Clinical Trials

Showing 701-720 of 1,498 trials

Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-14

NCT03439189

To validate the ability of the Methacetin Breath Test (MBT) to detect clinically significant portal hypertension (CSPH)/severe portal hypertension (SPH) defined as hepatic venous pressure gradient (HVPG) ≥ 10 mmHg and HVPG ≥ 12 mmHg respectively, in patients with non-alcoholic steatohepatitis (NASH) during the course of treatment with Conatus's investigational product emricasan/placebo.

NASH - Nonalcoholic SteatohepatitisCirrhosisPortal Hypertension

Meridian Bioscience, Inc.343 participantsStarted Aug 2016

Clichy, France

COMPLETEDNA

Equivalence of New Breath AnalyzerCompared to Currently BreathID System in Assessment of Liver Function

NCT02187601

The aim of the study is to confirm that the new generation state of the art breath analyzer gives equivalent results to the previous model of the Exalenz breath analyzer.

Chronic Liver Disease (CLD)Healthy Volunteers

Meridian Bioscience, Inc.20 participantsStarted Aug 2014

Tzrifin, Israel

COMPLETEDNA

Assessing Portal Hypertension With Methacetin Breath Test

NCT02143778

This study will be used to train an algorithm using Methacetin breath test (MBT) measures and to select a cut-off to determine presence or absence of Clinically Significant Portal Hypertension (CSPH) as defined by Hepatic Venous Gradient Pressure (HVPG) ≥ 10mmHg,

Patients With Compensated Liver Cirrhosis

Meridian Bioscience, Inc.246 participantsStarted Nov 2014

New Haven, Connecticut, United States • Durham, North Carolina, United States • Richmond, Virginia, United States +5 more locations

Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-14

Equivalence of New Breath AnalyzerCompared to Currently BreathID System in Assessment of Liver Function

Assessing Portal Hypertension With Methacetin Breath Test

Related Searches

Prediction Value of the BreathID 13C-Methacetin Breath Test for Hepatic Decompensation

Acamprosate Safe to Use in Individuals With Liver Disease.

Value on Survival of Liver Volume After an Acute Decompensation of an Alcoholic Cirrhosis

Porphyromonas Gingivalis and Severity of Fibrosis in Patients With Non-alcoholic Fatty Liver Disease

Observational Clinical Study of the Natural Course and Long-term Prognosis of Patients With Chronic Liver Disease

Carvedilol vs. Propranolol in Second Prophylaxis of Variceal Bleeding

Diagnosis of Nodules ≤2 cm Based on US and CEUS Compared With Current Clinical Procedure

The Acute Effects of Eucaloric and Hypocaloric Carbohydrate Restriction on Liver Fat Content and Metabolism in Obese Individuals

Research on Optimal Strategy of Hypoglycemic Therapy for Cirrhosis With Diabetes

Carvedilol for Prevention of Esophageal Varices Progression

Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease

Efficacy of Avatrombopag in Thrombocytopenic Patients With Chronic Liver Disease Undergoing an Elective Procedure

Effectiveness of Inactive Vitamin D Supplementation in Non-Alcoholic Fatty Liver Disease Patients

A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease

Research on the Clinical Characteristics and Key Diagnosis and Treatment Technology of Genetic and Metabolic Liver Disease

Prevalence of MAFLD in Patients With Type 2 Diabetes in Jiangsu Province of China

Anticoagulation for Advanced Cirrhotic Patients After TIPS